Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Temozolomide
Therapeutic Area : Oncology
Study Phase : Preclinical
Recipient : University of Central florida
Deal Size : Undisclosed
Deal Type : Financing
Ludwig Enterprises Inc (OTC:LUDG) Funds Incurable Brain Cancer Study
Details : The net proceeds will be used to fund a preclinical study on Glioblastoma (GBM), an incurable brain cancer, to potentially increase the efficacy of Merck's FDA approved drug Temodar (temozolomide).
Brand Name : Temodar
Molecule Type : Small molecule
Upfront Cash : Undisclosed
March 27, 2024
Lead Product(s) : Temozolomide
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Recipient : University of Central florida
Deal Size : Undisclosed
Deal Type : Financing
Lead Product(s) : Amino Acids Mixture
Therapeutic Area : Immunology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Ludwig Enterprises Announces Launch of New Nutraceutical and Strategic Marketing Plan
Details : NuGenea is a nutraceutical formulated with 20 different ingredients which have been scientifically shown to help fight chronic inflammation, which is a causative factor in illnesses such as cancer, diabetes, COPD and heart disease.
Brand Name : NuGenea
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 25, 2023
Lead Product(s) : Amino Acids Mixture
Therapeutic Area : Immunology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Mycobacterium Bovis Bacille Calmette-guerin Vaccine
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Emerson Urology Associates
Deal Size : Not Applicable
Deal Type : Not Applicable
Ludwig Enterprises and Emerson Urology Associates Plan Bladder Cancer BCG Immunotherapy Study
Details : Bacillus Calmette-Guérin (BCG) is a cancer vaccine that uses weakened bacteria to stimulate the immune system. BCG (mycobacterium bovis bacille calmette-guerin vaccine) has received U.S. FDA approval for the treatment of early-stage bladder cancer.
Brand Name : BCG
Molecule Type : Vaccine
Upfront Cash : Not Applicable
September 20, 2022
Lead Product(s) : Mycobacterium Bovis Bacille Calmette-guerin Vaccine
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Emerson Urology Associates
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?